Artiva Biotherapeutics (NASDAQ:ARTV) SVP Sells $27,885.95 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) SVP Heather Raymon sold 3,095 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $27,885.95. Following the completion of the sale, the senior vice president owned 148,228 shares in the company, valued at $1,335,534.28. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of ARTV stock opened at $7.87 on Friday. The business’s 50 day simple moving average is $8.41 and its 200 day simple moving average is $5.72. Artiva Biotherapeutics, Inc. has a one year low of $1.47 and a one year high of $14.53. The stock has a market capitalization of $194.55 million, a PE ratio of -2.22 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, research analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ARTV. Prelude Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Bank of America Corp DE boosted its holdings in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $53,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $58,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000.

Analysts Set New Price Targets

Several analysts recently commented on ARTV shares. Needham & Company LLC upped their target price on Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. HC Wainwright increased their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Wedbush increased their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.